Medanta (Global Health) Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹38,598 Cr
- Book Value
- ₹147
- Stock P/E
- 67.4
- Dividend Yield
- 0.03%
- ROE
- 15.2%
- ROCE
- 17.1%
- PEG Ratio
- 0.84
- EV/EBITDA
- 35.8
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Technical snapshot
EOD ·Global Health Ltd (Medanta) closed at ₹1,417.20 on 19 August 2026, down 1.8% on the day, 4.8% above its 50-day average, 4.9% below its 52-week high, with volume at 0.27× its 20-session average.
- RSI 14
- 53.5
- vs 50-day SMA
- +4.8%
- vs 200-day SMA
- +18.0%
- From 52-week high
- -4.9%
- Relative volume
- 0.27×
- 20-day return
- +4.7%
End-of-day prices from exchange-published files (NSE/BSE bhavcopy), updated after market close. Descriptive statistics, not investment advice.
Medanta share price today
Global Health (NSE: MEDANTA) operates the Medanta hospitals — flagship Gurugram plus a north-India network expanding through Lucknow, Patna and Noida — built by Dr Naresh Trehan around a simple thesis: tertiary-care depth (hearts, transplants, oncology, neuro) in cities where world-class treatment previously meant a flight. The model produces the sector’s signature economics as units mature: an 81% five-year profit CAGR as young hospitals cross breakeven and mature ones mint cash.
At 67.4×, the scarcity premium on quality hospital beds is real, but so is the arithmetic: a PEG of 0.84 only helps if the ramp keeps ramping.
The maturation ladder
Hospital economics are a J-curve: a new unit burns for 2–3 years, breaks even, then compounds EBITDA for decades as case mix enriches toward complex procedures. Medanta’s ladder is deliberately staggered — Gurugram mature, Lucknow scaling fast, Patna climbing, Noida just opened — so consolidated numbers understate the mature-unit profitability still surfacing. North-India catchments (UP, Bihar) have the country’s worst bed density: demand is structural, not cyclical.
Watch-items: Noida’s ramp pace, payor mix (insurance penetration lifts realisations), regulatory pricing interventions (the sector’s recurring scare), and key-person continuity around the founder-clinician brand.
The numbers
Financial snapshot — 5 August 2026
| Metric | Value |
|---|---|
| Market cap | ₹38,598 Cr |
| P/E (TTM) | 67.4 |
| EV/EBITDA | 35.8 |
| Operating margin | 20.9% |
| ROE / ROCE | 15.2% / 17.1% |
| Debt to equity | 0.30 |
| Sales CAGR (5y) | 25.0% |
| Profit CAGR (5y) | 80.7% |
| Promoter holding | 33.0% |
| EPS (TTM) | ₹21.29 |
Medanta share price target 2026 to 2030
EPS base ₹21.29 (TTM). The 81% CAGR is J-curve math that must decelerate; scenarios do. Bear: ramps slow and pricing intervention lands — 12% growth, multiple at 38×. Base: units mature on schedule — 18% growth at 52×. Bull: case-mix enrichment plus new-bed announcements — 24% growth at 65×.
From ₹1,435, the base case is ≈ +76% over four and a half years — and the bear case is essentially flat (−1%). The staggered maturation ladder supports the range, but slower occupancy or weaker returns from new hospitals would change it materially.
Reasons to own Medanta (at the right price)
- A hospital J-curve portfolio mid-climb — profits surface for years without new capex.
- Tertiary-care depth in India’s most under-bedded catchments.
- 81% profit CAGR shows the model working; PEG 0.84 says growth is fairly bought.
- Clinician-founder brand that recruits the specialists who bring the patients.
- Insurance penetration is a decade-long realisation tailwind.
The risks: 67× forgives no ramp delays, hospital pricing is a perennial regulatory target, 33% promoter holding is modest, and the brand’s founder-dependence is real.
What to weigh at the current price
Medanta’s hospital maturity ladder can sustain growth as newer units scale, but a 67.4× multiple leaves little room for a slow ramp. Occupancy, case mix, Noida losses and cash returns from new beds are the key checks.
FAQ
What is the Medanta share price target for 2030? The table above presents bear, base and bull paths through 2030. Each depends on the stated EPS-growth and valuation assumptions; none is a guaranteed outcome.
Why is profit growing so much faster than revenue? Operating leverage: new hospitals cross breakeven and every incremental occupied bed drops largely to EBITDA. The 81% profit CAGR against 25% sales CAGR is that leverage surfacing.
What could break the story? A regulated cap on procedure pricing (periodically threatened), a stalled ramp at a new unit, or losing marquee clinical teams — hospitals are talent franchises wearing real estate.
When are Medanta’s next results? Check the results calendar and confirm the announced date in the exchange filing.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.